ProKidney (PROK)
Nasdaq Market Closed
ProKidney Corp. is a clinical-stage biotechnology company focused on developing cell-based therapies for chronic kidney disease, with an emphasis on patients whose kidney damage is associated with diabetes. Its lead candidate, REACT, or Renal Autologous Cell Therapy, is designed to use a patient’s own renal cells in an effort to preserve kidney function and slow disease progression.
Chronic kidney disease is a major global health burden and can eventually lead to dialysis, kidney transplantation or severe cardiovascular complications. Diabetic kidney disease is one of the most common causes of advanced kidney failure. ProKidney’s approach is intended to address the underlying decline in kidney function rather than simply manage symptoms or related risk factors.
REACT is manufactured from kidney tissue obtained from the individual patient. Selected renal cells are expanded and prepared for reintroduction into the kidney, where the therapy is intended to support repair or stabilization of kidney function. Because the therapy is autologous, it is based on the patient’s own cells rather than donor-derived or off-the-shelf material.
The company’s pipeline is centered on advancing REACT through clinical development for severe diabetic kidney disease. As with other biotechnology businesses at this stage, ProKidney’s value depends heavily on clinical trial results, manufacturing execution, regulatory review and the ability to demonstrate a meaningful benefit over current standards of care. The company occupies a distinctive niche within kidney therapeutics, combining regenerative medicine, cell processing and nephrology in a field where treatment options remain limited for patients approaching kidney failure.
Last updated
- Market Cap
- 355M
- P/E
- —
- P/FCF
- —
- P/S
- 399.32
- Enterprise Value
- 253.1M
- Sector
- Health Care
- Industry
- Biological Products, Except Diagnostic Substances
- Address
- 2000 FRONTIS PLAZA BLVD., WINSTON-SALEM, NC, 27103
ProKidney Reports Full Year 2025 Financial Results and Business Highlights
ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025
Play Likely Earnings Beat With 3 Top-Ranked Stocks
ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
ProKidney Announces Proposed $125 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates
ProKidney Reports Business Updates and First Quarter 2024 Financial Results
ProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical Operations
ProKidney Reports Full Year 2023 Financial Results and Recent Corporate Highlights
Here's Why ProKidney Corp. (PROK) Is a Great 'Buy the Bottom' Stock Now
ProKidney Appoints Nikhil Pereira-Kamath, MBA, as Chief Business Officer
ProKidney to Participate in a Fireside Chat at the Upcoming Evercore ISI 6th Annual HEALTHCONx Conference
After Plunging -37.39% in 4 Weeks, Here's Why the Trend Might Reverse for ProKidney Corp. (PROK)
ProKidney Reports Third Quarter Financial Results
ProKidney Announces Positive Interim Data from RMCL-002 Phase 2 Clinical Trial of Renal Autologous Cell Therapy (REACT®) for Diabetic CKD and Provides Corporate Updates
ProKidney Announces Four Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2023
ProKidney Corp. (PROK) Loses -54.93% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
ProKidney to Participate in Fireside Chat at the Morgan Stanley Global Healthcare Conference
ProKidney Reports Second Quarter Financial Results and Recent Corporate Highlights
ProKidney Announces Closing of Purchase of Manufacturing Facility in Greensboro, NC
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 355M
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 253.1M
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- -0.35
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 399.32
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- -1.56
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 284.7
- EPS
- -0.35
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- -150.06M
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- 7.06%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -24.69%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 9.06
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 9.06
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 3.93
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 862.79K
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 1.73
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | 226K | 225K | 217K | 221K | 230K |
| Gross profit | 226K | 225K | 217K | 221K | 230K |
| Operating income | -44.93M | -45.37M | -38.54M | -39.71M | -41.39M |
| EBITDA | -43.28M | -43.53M | -36.87M | -38.24M | -39.79M |
| Net income | -20.04M | -19.23M | -16.47M | -16.55M | -16.73M |
| Basic EPS | -0.14 | -0.14 | -0.12 | -0.13 | -0.13 |
| Diluted EPS | -0.14 | -0.14 | -0.12 | -0.13 | -0.13 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 292.78M | 335.57M | 351.61M | 372.13M | 406.06M |
| Total liabilities | 29.68M | 34.78M | 33.27M | 32.68M | 36.08M |
| Total equity | -1.02B | -1.01B | -1.01B | -1B | -998.55M |
| Cash & equivalents | 101.9M | 108.54M | 95.32M | 84.94M | 97.81M |
| Current assets | 234.9M | 280.68M | 299.99M | 324.44M | 359.66M |
| Current liabilities | 25.93M | 30.74M | 29.06M | 28.26M | 32.81M |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | -41.68M | -32.51M | -26.6M | -31.42M | -29.59M |
| Investing cash flow | 34.83M | 28.09M | 29.02M | 18.57M | 28.29M |
| Financing cash flow | 215K | 17.63M | 7.96M | -14K | -12K |
| Change in cash | -6.64M | 13.21M | 10.38M | -12.87M | -1.32M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 8-K — PROKIDNEY CORP. | View Filing | |
| edgar index | 4 — PROKIDNEY CORP. | View Filing | |
| edgar index | 4 — PROKIDNEY CORP. | View Filing | |
| edgar index | 4 — PROKIDNEY CORP. | View Filing | |
| edgar index | 4 — PROKIDNEY CORP. | View Filing | |
| edgar index | 4 — PROKIDNEY CORP. | View Filing | |
| edgar index | 4 — PROKIDNEY CORP. | View Filing | |
| edgar index | 4 — PROKIDNEY CORP. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — Pereira Brian JG | View Filing | |
| form 4 | Form 4 — Legorreta Pablo G. | View Filing | |
| form 4 | Form 4 — Sinha Uma | View Filing | |
| form 4 | Form 4 — DOYLE WILLIAM F | View Filing | |
| form 4 | Form 4 — Fox Jennifer A. | View Filing | |
| form 4 | Form 4 — Jimenez Santos Jose Ignacio | View Filing | |
| form 4 | Form 4 — Lotvin Alan | View Filing | |
| edgar index | 10-Q — PROKIDNEY CORP. | View Filing | |
| edgar index | 8-K — PROKIDNEY CORP. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | DEF 14A — PROKIDNEY CORP. | View Filing | |
| edgar index | DEFA14A — PROKIDNEY CORP. | View Filing | |
| edgar index | ARS — PROKIDNEY CORP. | View Filing | |
| edgar index | 10-K — PROKIDNEY CORP. | View Filing | |
| edgar index | 8-K — PROKIDNEY CORP. | View Filing | |
| edgar index | S-8 — PROKIDNEY CORP. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| ten k section | 10-K — business | View Filing | |
| ten k section | 10-K — mda | View Filing | |
| ten k section | 10-K — risk_factors | View Filing | |
| edgar index | 4 — PROKIDNEY CORP. | View Filing | |
| edgar index | 4 — PROKIDNEY CORP. | View Filing | |
| edgar index | 4 — PROKIDNEY CORP. | View Filing | |
| edgar index | 4 — PROKIDNEY CORP. | View Filing | |
| form 4 | Form 4 — Culleton Bruce | View Filing | |
| form 4 | Form 4 — Girolamo Todd C | View Filing | |
| form 4 | Form 4 — Weber Darin J. | View Filing | |
| form 4 | Form 4 — Coulston James | View Filing | |
| edgar index | SCHEDULE 13G — PROKIDNEY CORP. | View Filing | |
| edgar index | 8-K — PROKIDNEY CORP. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — PROKIDNEY CORP. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | EFFECT — PROKIDNEY CORP. | View Filing | |
| edgar index | 4 — PROKIDNEY CORP. | View Filing | |
| form 4 | Form 4 — Pereira Brian JG | View Filing | |
| form 4 | Form 4 — Pereira Brian JG | View Filing | |
| edgar index | 144 — PROKIDNEY CORP. | View Filing | |
| edgar index | 144 — PROKIDNEY CORP. | View Filing | |
| form 4 | Form 4 — Pereira Brian JG | View Filing | |
| form 4 | Form 4 — Pereira Brian JG | View Filing | |
| edgar index | 10-Q — PROKIDNEY CORP. | View Filing | |
| edgar index | 8-K — PROKIDNEY CORP. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | DEL AM — PROKIDNEY CORP. | View Filing | |
| edgar index | POS AM — PROKIDNEY CORP. | View Filing | |
| edgar index | 8-K — PROKIDNEY CORP. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 10-Q — PROKIDNEY CORP. | View Filing | |
| edgar index | 8-K — PROKIDNEY CORP. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G/A — PROKIDNEY CORP. | View Filing | |
| edgar index | SCHEDULE 13G/A — PROKIDNEY CORP. | View Filing | |
| edgar index | 8-K12B/A — PROKIDNEY CORP. | View Filing | |
| edgar index | 8-K — PROKIDNEY CORP. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 424B5 — PROKIDNEY CORP. | View Filing | |
| edgar index | 8-K — PROKIDNEY CORP. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — PROKIDNEY CORP. | View Filing | |
| edgar index | 4 — PROKIDNEY CORP. | View Filing | |
| edgar index | 8-K — PROKIDNEY CORP. | View Filing | |
| edgar index | 144 — PROKIDNEY CORP. | View Filing | |
| form 4 | Form 4 — Weber Darin J. | View Filing | |
| edgar index | POS AM — PROKIDNEY CORP. | View Filing | |
| edgar index | EFFECT — PROKIDNEY CORP. | View Filing |